Nymox Pharmaceutical Corp. amended its 2025 annual report solely to correct the independent auditor’s report date from September 10 to September 11, 2026. The amendment says no other changes were made apart from that correction, updated signature and certification dates, and exhibit-index changes; it speaks as of the original filing date. The auditor’s opinion was not modified in respect of the going-concern matter, but the auditor highlighted material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern.
For 2025, Nymox reported no revenue, a $4.275 million net loss versus $4.492 million in 2024, and a $3.677 million operating loss versus $4.283 million. It used $1.806 million in operating cash. At year-end, cash was approximately $6,388 and negative working capital was $9,306,391. Management said cash and anticipated product-sale funds would not cover planned operations and research and development for the next 12 months, and said it intended to seek additional financing.
NX-1207’s UK marketing authorization application remained under review. The Danish application had run out of time and would require an extension by resubmission with a new fee; the FDA issued a Refusal to File Letter in May 2022.
Nymox Pharmaceutical Corporation (NYMXF) filed an amended Form 20-F/A mainly to add missing interactive data, while reaffirming results for the year ended December 31, 2025. The company reported no revenue, a net loss of $4.3 million, and negative equity of $9.3 million.
Cash was only $6,000 with a working capital deficit of about $9.3 million, and both management and the auditor highlight a material going concern uncertainty. Nymox continues to pursue approval of fexapotide triflutate (NX‑1207) for BPH and prostate cancer after earlier Phase 3 failures, with an FDA Refusal to File letter and a U.K. MAA still under review. The business remains dependent on external financing, significant stock-based compensation, and highly concentrated ownership, with insiders controlling over half of outstanding shares.
Nymox Pharmaceutical Corporation (NYMXF) filed its annual Form 20‑F detailing continued development-stage operations with no revenues and ongoing losses. For 2025, the company reported a net loss of $4.3 million, total assets of about $576,000, and an accumulated deficit of roughly $216.7 million.
Cash was only $6,000 at December 31 2025 against a negative working capital position of about $9.3 million, and both management and the auditor highlight a material uncertainty about the company’s ability to continue as a going concern. Nymox remains pre‑revenue, developing its lead drug fexapotide triflutate (NX‑1207) for benign prostatic hyperplasia and low‑grade prostate cancer. Earlier Phase 3 BPH trials initially failed primary endpoints at 12 months but later met a long‑term symptomatic endpoint in extension studies.
The company has faced regulatory setbacks, including an FDA Refusal to File letter in 2022 and a Danish Marketing Authorization Application that lapsed and would require resubmission with a new fee, while a U.K. MAA remains under review. Operations are funded primarily through equity and related‑party financing, with 102,040,140 shares outstanding at year‑end 2025 and significant option overhang. Insiders and directors, led by CEO Paul Averback, beneficially control just over 55% of the shares.
NYMOX PHARMACEUTICAL CORP (NYMXF) reports the results of a shareholder vote held in August 2026 to elect its Board of Directors. Shareholders elected Dr. Paul Averback (Chairman), Dr. David Morse, Dr. Russell Thomson, Dr. Kresimir Pucaj, and Robert Lachance.
Of 105,040,140 shares issued and outstanding, 47,885,624 shares (45.59%) were voted. The motion to elect directors received 47,066,029 shares (98.29%) in favor, 0 against, and 819,595 shares (1.71%) withheld/abstaining, with no spoiled ballots or non-votes. Voting by shareholders of record as of August 4, 2026 was closed and locked by Computershare on August 26, 2026 at 5:00 pm EST, and the nominees were declared duly elected at a virtual meeting on August 28, 2026.
Nymox Pharmaceutical Corporation, a foreign private issuer, reports that it will hold a Special Shareholder's Meeting on August 28, 2026 to elect the members of its Board of Directors. A Notice of Meeting and a Management Proxy Circular accompany this announcement.
The company also states that its annual report on Form 20-F for the financial year ended December 31, 2025 has been delayed mainly due to previously reported changes in management and the Board, and is planned to be filed with the U.S. Securities and Exchange Commission. Nymox points to its website, www.nymox.com, for current 2026 updates.
Nymox Pharmaceutical Corporation submitted a Form 6-K noting it has issued a press release about its drug candidate Nymozarfex (TM). The company explains that its current plans for Nymozarfex are focused on re-submission in the United States for marketing approval and that related drug reviews have been updated.
The June 2, 2026 press release is furnished as Exhibit 99.1 to this report and is specifically described as furnished rather than filed under the U.S. securities laws.
Nymox Pharmaceutical Corporation submitted a Form 6-K as a foreign private issuer. The company reports that it issued a press release on March 27, 2026 describing upcoming changes to its Board of Directors, a share purchase by its Chief Executive Officer, and a remembrance note for its late Co-Chairman James G. Robinson. The press release is included as Exhibit 99.1 and is furnished, not filed, under the Securities Exchange Act of 1934.
Nymox Pharmaceutical Corporation filed a 6-K stating that the U.S. District Court for the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Christopher Riley’s complaint and dismissed the case, with prejudice.
A dismissal “with prejudice” means the case is closed and cannot be refiled on the same claims. This removes an outstanding legal matter for Nymox without indicating any financial terms. The report was signed on November 7, 2025.
Nymox Pharmaceutical Corporation reported a final court outcome related to its 2023 litigation. The Supreme Court of the Bahamas issued its final order requiring Mr. Lanham, Mr. Riley, CRNSV, and other claimants to pay the Company $203,075.40. This award represents a percentage of expenses previously noted by the Company. The decision provides a defined cash recovery tied to the case and concludes this matter with a court-ordered payment to Nymox.
Nymox Pharmaceutical Corporation reported an insider share purchase. The company disclosed on Form 6-K that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025. The update records the transaction by the company’s chief executive and reflects an increase in his personal share ownership.